– Genexine to receive an upfront payment and entitled to tiered, single-digit royalties on net sales of HyLeukin plus milestone payments from I-Mab Biopharma (I-Mab).
– I-Mab receives exclusive development and commercialization rights to HyLeukin in Mainland China, Taiwan, Hong Kong…
